Spinophilin: A new tumor suppressor at 17q21

Current Molecular Medicine

Volumn 12, Issue 5, 2012, Pages 528-535

  Carner, A ^a,b  

^a UNIVERSITY OF SEVILLE   (Spain)

^b CSIC   (Spain)

Author keywords

17q21; Cancer; Cell cycle; Retinoblastoma; Spinophilin; Tumor suppressor

Indexed keywords

CADHERIN; DOUBLECORTIN; MESSENGER RNA; PROHIBITIN; PROTEIN P53; RETINA S ANTIGEN; RETINOBLASTOMA PROTEIN; SPINOPHILIN;

ARTICLE; BASAL CELL CARCINOMA; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CARCINOGENESIS; CARCINOSARCOMA; CELL ADHESION; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CHROMOSOME 17Q; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CYTOGENETICS; DENDRITIC CELL; DOWN REGULATION; ENDOMETRIUM CARCINOMA; ENZYME ACTIVE SITE; EXCITATION CONTRACTION COUPLING; GENE LOCUS; GENE MAPPING; GENE MUTATION; GENE OVEREXPRESSION; GENETIC LINKAGE; HETEROZYGOSITY LOSS; HUMAN; KIDNEY CARCINOMA; KNOCKOUT MOUSE; LIFESPAN; LOSS OF FUNCTION MUTATION; LUNG ADENOCARCINOMA; LUNG TUMOR; MICROSATELLITE INSTABILITY; NERVE CELL PLASTICITY; NONHUMAN; OLIGODENDROGLIOMA; OVARY CARCINOMA; PHENOTYPE; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; SENESCENCE; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TUMOR CELL; TUMOR SUPPRESSOR GENE; WILD TYPE;

MUS;

EID: 84860990671     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652412800619987     Document Type: Article

References (80)

1. Allen PB, Ouimet CC, Greengard P. Spinophilin, a novel protein phosphatase 1 binding protein localized to dendritic spines. Proc Natl Acad Sci USA 1997; 94: 9956-9961.
2. Satoh A, Nakanishi H, Obaishi H, et al. Neurabin- II/spinophilin. An actin filament-binding protein with one pdz domain localized at cadherin-based cell-cell adhesion sites. J Biol Chem 1998; 273: 3470-345.
3. Sarrouilhe D, di Tommaso A, Metaye T, Ladeveze V. Spinophilin: from partners to functions. Biochimie 2006; 88: 1099-1113.
4. Kuntziger T, Landsverk HB, Collas P, Syljuasen RG. Protein phosphatase 1 regulators in DNA damage signaling. Cell Cycle 2011; 10.
5. Vivo M, Calogero RA, Sansone F, et al. The human tumor suppressor arf interacts with spinophilin/neurabin II, a type 1 protein-phosphatase-binding protein. J Biol Chem 2001; 276: 14161-14169.
6. Brady AE, Wang Q, Colbran RJ, et al. Spinophilin stabilizes cell surface expression of alpha 2B-adrenergic receptors. J Biol Chem 2003; 278: 32405-32412.
7. Wang Q, Zhao J, Brady AE, et al, Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors. Science 2004; 304: 1940-1944.
8. Allen PB, Zachariou V, Svenningsson P, et al. Distinct roles for spinophilin and neurabin in dopamine-mediated plasticity. Neuroscience 2006; 140: 897-911.
9. Hsieh-Wilson LC, Allen PB, Watanabe T, Nairn AC, Greengard P. Characterization of the neuronal targeting protein spinophilin and its interactions with protein phosphatase-1. Biochemistry 1999; 38: 4365-4373.
10. Muly EC, Smith Y, Allen P, Greengard P. Sub cellular distribution of spino philin immunolabeling in primate prefrontal cortex: localization to and within dendritic spines. J Comp Neurol 2004; 469: 185-197.
11. Ouimet CC, Katona I, Allen P, Freund TF, Greengard P. Cellular and subcellular distribution of spinophilin, a PP1regulatory protein that bundles F-actin in dendritic spines. J Comp Neurol 2004; 479: 374-388.
12. Yan Z, Hsieh-Wilson L, Feng J, et al. Protein phosphatase 1modulation of neostriatal AMPA channels: regulation by DARPP-32 and spinophilin. Nat Neurosci 1999; 2: 13-17.
13. Hsieh-Wilson LC, Benfenati F, Snyder GL, et al. Phosphorylation of spinophilin modulates its interaction with actin filaments. J Biol Chem 2003; 278: 1186-1194.
14. Stafstrom-Davis CA, Ouimet CC, Feng J, et al. Impaired conditioned taste aversion learning in spinophilin knockout mice. Learn Mem 2001; 8: 272-278.
15. Takeichi M, Abe K. Synaptic contact dynamics controlled by cadherin and catenins. Trends Cell Biol 2005; 15: 216-221.
16. Mizoguchi A. Role of vesicle fusion mechanism and cell adhesion molecules in growth cone elongation and synaptogenesis. Kaibogaku Zasshi 1999; 74: 473-483.
17. Charlton JJ, Allen PB, Psifogeorgou K, et al. Multiple actions of spino philin regulate mu opioid receptor function. Neuron 2008; 58: 238-247.
18. da Costa-Goncalves AC, Tank J, Plehm R, et al. Role of the multi domain protein spinophilin in blood pressure and cardiac function regulation. Hypertension 2008; 52: 702-707.
19. Petzhold D, da Costa-Goncalves AC, Gross V, Morano I. Spinophilin is required for normal morphology, Ca(2+) homeostasis and contraction but dispensable for betaadrenergic stimulation of adult cardiomyocytes. J Muscle Res Cell Motil 2011; 32: 243-248.
20. Nag S, Wang Q, Limbird LE, Mokha SS. Knockout of spinophilin, an endogenous antagonist of arrestin-dependent alpha2-adrenoceptor functions, enhances receptor-mediated antinociception yet does not eliminate sex-related differences. Behav Brain Res 2009; 197: 457-461.
21. Wang Q, Limbird LE. Regulation of alpha2AR trafficking and signaling by interacting proteins. Biochem Pharmacol 2007; 73: 1135-1145.
22. Shaw AS, Filbert EL. Scaffold proteins and immune-cellsignalling. Nat Rev Immunol 2009; 9: 47-56.
23. Meng X, Kanwar N, Du Q, et al. PPP1R9B (Neurabin 2):involvement and dynamics in the NK immunological synapse. Eur J Immunol 2009; 39: 552-560.
24. Querzoli P, Albonico G, di Iasio MG, et al. Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women. Breast Cancer Res Treat 2001; 66: 135-142.
25. Caduff RF, Svoboda-Newman SM, Ferguson AW, Frank TS. Comparison of alterations of chromosome 17 in carcinoma of the ovary and of the breast. Virchows Arch 1999; 434: 517-522.
26. Maitra A, Tavassoli FA, Albores-Saavedra J, et al. Molecular abnormalities associated with secretory carcinomas of the breast. Hum Pathol 1999; 30: 1435-1440.
27. Abujiang P, Mori TJ, Takahashi T, et al. Loss of hetero zygosity (LOH) at 17q and 14q in human lung cancers. Oncogene 1998; 17: 3029-3033.
28. Porter DE, Steel CM, Cohen BB, et al. Genetic linkage analysis applied to unaffected women from families with breast cancer can discriminate high- from low-risk individuals. Br J Surg 1993; 80: 1381-5138.
29. Porter DE, Cohen BB, Wallace MR, et al. Breast cancer incidence, pene trance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg 1994; 81: 1512-1515.
30. Cohen BB, Porter DE, Wallace MR, Carothers A, Steel CM. Linkage of a major breast cancer gene to chromosome 17q12-21: results from 15 Edinburgh families. Am J Hum Genet 1993; 52: 723-729.
31. Smith SA, Easton DF, Ford D, et al. Genetic heterogeneity and localization of a familial breast-ovarian cancer gene on chromosome 17q12-q21. Am J Hum Genet 1993; 52: 767-776.
32. Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The breast cancer linkage consortium. Am J Hum Genet 1993; 52: 678-701.
33. Tseng SL, Yu IC, Yue CT, et al. Allelic loss at BRCA1, BRCA2, and adjacent loci in relation to TP53 abnormality in breast cancer. Genes Chromosomes Cancer 1997; 20: 377-382.
34. Molina-Pinelo S, Ferrer I, Blanco-Aparicio C, et al, Down regulation of spinophilin in lung tumours contributes to tumourigenesis. J Pathol 2011; 225: 73-82.
35. Castro ME, Ferrer I, Cascon A, et al. PPP1CA contributes to the senescence program induced by oncogenic Ras. Carcinogenesis 2008; 29: 491-49.
36. Nelson DA, Krucher NA, Ludlow JW. High molecular weight protein phosphatase type 1 dephosphorylates the retinoblastoma protein. J Biol Chem 1997; 272: 4528-4535.
37. Wang RH, Liu CW, Avramis VI, Berndt N. Protein phosphatase 1alpha-mediated stimulation of apoptosis is associated with dephosphorylation of the retinoblastoma protein. Oncogene 2001; 20: 6111-6122.
38. Alberts AS, Thorburn AM, Shenolikar S, Mumby MC, Feramisco JR. Regulation of cell cycle progression and nuclear affinity of the retinoblastoma protein by proteinphosphatases. Proc Natl Acad Sci USA 1993; 90: 388-392.
39. Berndt N, Dohadwala M, Liu CW. Constitutively active protein phosphatase 1alpha causes Rb-dependent G1 arrest in human cancer cells. Curr Biol 1997; 7: 375-386.
40. Berndt N, Ludlow JW. Interaction between the retinoblastoma protein and protein phosphatase 1 during the cell cycle. Methods Mol Biol 2004; 281: 17-32.
41. Rubin E, Tamrakar S, Ludlow JW. Protein phosphatase type 1, the product of the retinoblastoma susceptibility gene, and cell cycle control. Front Biosci 1998; 3: D1209-D1219.
42. Abnizova I, Boekhorst R, Walter K, Gilks WR. Some statistical properties of regulatory DNA sequences, and their use in predicting regulatory regions in the Drosophila genome: the fluffy-tail test. BMC Bioinformatics 2005; 6: 109.
43. Narita M, Nunez S, Heard E, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003; 113: 703-716.
44. Narita M, Lowe SW. Executing cell senescence. Cell Cycle 2004; 3: 244-246.
45. Mooi WJ, Peeper DS. Onco gene-induced cell senescence-- halting on the road to cancer. N Engl J Med 2006; 355: 1037-1046.
46. Lehmann BD, Brooks AM, Paine MS, et al. Distinct roles for p107 and p130 in Rb-independent cellular senescence. Cell Cycle 2008; 7: 1262-1268.
47. Ruiz L, Traskine M, Ferrer I, et al. Characterization of the p53 response to oncogene-induced senescence. PLoS ONE 2008; 3: e3230.
48. Berndt N. Protein dephosphorylation and the intracellular control of the cell number. Front Biosci 1999; 4: D22-D42.
49. Ferrer BAC, Peregrino S, Cañamero M, and Carnero A, Spinophilin regulates pRb phosphorylation through PP1aactivity and acts as a tumor suppressor gene in the absence of p53. submitted.
50. Vergel M, Marin JJ, Estevez P, Carnero A. Cellular senescence as a target in cancer control. J Aging Res 2010; 2011: 725365.
51. Ferrer I, Peregrino S, Cañamero M, et al. Spinophilin loss contributes to tumorigenesis in vivo. Cell Cycle 2011; 10: 1-8.
52. Blagosklonny MV. Aging-suppressants: cellular senescence (hyperactivation) and its pharmacologic deceleration. Cell Cycle 2009; 8: 1883-1887.
53. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88: 593-602.
54. Efeyan A, Garcia-Cao I, Herranz D, Velasco-Miguel S, Serrano M. Tumour biology: Policing of oncogene activity by p53. Nature 2006; 443: 159.
55. Carnero A, Lleonart ME. Epigenetic mechanisms in senescence, immortalisation and cancer. Biol Rev Camb Philos Soc 2011; 86(2): 443-455.
56. Collado M, Gil J, Efeyan A, et al. Tumour biology: senescence in premalignant tumours. Nature 2005; 436: 642.
57. Tsukada M, Prokscha A, Oldekamp J, Eichele G. Identification of neurabin II as a novel doublecortin interacting protein. Mech Dev 2003; 120: 1033-1043.
58. Bielas SL, Serneo FF, Chechlacz M, et al. Spinophilinfacilitates dephosphorylation of doublecortin by PP1 tomediate microtubule bundling at the axonal wrist. Cell 2007;129: 579-591.
59. Feng J, Yan Z, Ferreira A, et al. Spinophilin regulates theformation and function of dendritic spines. Proc Natl Acad SciUSA 2000; 97: 9287-9292.
60. Santra M, Zhang X, Santra S, Jiang F, Chopp M. Ectopic doublecortin gene expression suppresses the malignant phenotype in glioblastoma cells. Cancer Res 2006; 66: 11726-11735.
61. Santra M, Santra S, Roberts C, Zhang RL, Chopp M. Doublecortin induces mitotic microtubule catastrophe and inhibits glioma cell invasion. J Neurochem 2009; 108: 231-245.
62. Santra M, Santra S, Buller B, et al. Effect of doublecortin on self-renewal and differentiation in brain tumor stem cells. Cancer Sci 2011; 102: 1350-1357.
63. De Marchis L, Cropp C, Sheng ZM, Bargo S, Callahan R. Candidate target genes for loss of heterozygosity on human chromosome 17q21. Br J Cancer 2004; 90: 2384-2389.
64. Schmutzler RK, Homann A, Bierhoff E, et al. Detection of genetic alterations in sporadic breast tumors. Gynakol Geburtshilfliche Rundsch 1995; 35 Suppl 1: 63-67.
65. Patel U, Grundfest-Broniatowski S, Gupta M, Banerjee S. Microsatellite instabilities at five chromosomes in primary breast tumors. Oncogene 1994; 9: 3695-3700.
66. Sirchia SM, Sironi E, Grati FR, et al. Losses of hetero zygosity in endometrial adenocarcinomas: positive correlations with histo pathological parameters. Cancer Genet Cytogenet 2000; 121: 156-162.
67. Emmert-Buck MR, Chuaqui R, Zhuang Z, et al. Molecular analysis of synchronous uterine and ovarian endometrioid tumors. Int J Gynecol Pathol 1997; 16: 143-148.
68. Shiina H, Breault JE, Basset WW, et al. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer. Cancer Res 2005; 65: 2130-2138.
69. Dumur CI, Dechsukhum C, Ware JL, et al. Genome-wide detection of LOH in prostate cancer using human SNP microarray technology. Genomics 2003; 81: 260-269.
70. Gao X, Zacharek A, Grignon DJ, et al. Localization of potential tumor suppressor loci to a < 2 Mb region on chromosome 17q in human prostate cancer. Oncogene 1995; 11: 1241-1247.
71. Berney CR, Fisher RJ, Yang J, Russell PJ, Crowe PJ. Genomic alterations (LOH, MI) on chromosome 17q21-23 and prognosis of sporadic colorectal cancer. Int J Cancer 2000; 89: 1-7.
72. Lin XQ, Liang Y, Ding SP, Li JC. Genetic instability on chromosome 17q21 in gastric cancer of Chinese patients. Shi Yan Sheng Wu Xue Bao 2005; 38: 148-156.
73. Foster K, Crossey PA, Cairns P, et al. Molecular genetic investigation of sporadic renal cell carcinoma: analysis of allele loss on chromosomes 3p, 5q, 11p, 17 and 22. Br J Cancer 1994; 69: 230-234.
74. Gotte K, Riedel F, Coy JF, Spahn V, Hormann K. Salivarygland carcinosarcoma: immunohistochemical, molecular genetic and electron microscopic findings. Oral Oncol 2000; 36: 360-364.
75. Sironi E, Cerri A, Tomasini D, et al. Loss of heterozygosity on chromosome 4q32-35 in sporadic basal cell carcinomas: evidence for the involvement of p33ING2/ING1L and SAP30 genes. J Cutan Pathol 2004; 31: 318-322.
76. French PJ, Swagemakers SM, Nagel JH, et al, Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res 2005; 65: 11335-11344.
77. Sun L, Hui AM, Su Q, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006; 9:287-300.
78. Bredel M, Bredel C, Juric D, et al, Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res 2005; 65: 8679-8689.
79. Gilks CB, Vanderhyden BC, Zhu S, van de Rijn M, Longacre TA, Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 2005; 96: 684-694.
80. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006; 103: 2794-2799.